{"id":1401,"date":"2017-02-21T08:56:10","date_gmt":"2017-02-21T07:56:10","guid":{"rendered":"http:\/\/semmelweis.hu\/onkologiai-kozpont\/?page_id=1401"},"modified":"2024-04-02T11:52:58","modified_gmt":"2024-04-02T09:52:58","slug":"daganatkezelesben-alkalmazott-hatoanyagok-lehetseges-mellekhatasai","status":"publish","type":"page","link":"https:\/\/semmelweis.hu\/onkologiai-kozpont\/betegellatas\/daganatkezelesben-alkalmazott-hatoanyagok-lehetseges-mellekhatasai\/","title":{"rendered":"Dagnatellenes gy\u00f3gyszeres kezel\u00e9sek"},"content":{"rendered":"<p style=\"text-align: justify\">A mindennapi onkol\u00f3giai ell\u00e1t\u00e1sban rendk\u00edv\u00fcl sok daganatellenes k\u00e9sz\u00edtm\u00e9nyt alkalmaznak. Az al\u00e1bbiakban a leggyakrabban haszn\u00e1lt gy\u00f3gyszerek r\u00f6vid, k\u00f6z\u00e9rthet\u0151 \u00f6sszefoglal\u00f3inak linkgy\u0171jtem\u00e9ny\u00e9t tal\u00e1lja. Az egyes gy\u00f3gyszerek nev\u00e9re kattintva az <a href=\"https:\/\/www.ema.europa.eu\/\" target=\"_blank\" rel=\"noopener\">Eur\u00f3pai Gy\u00f3gyszer\u00fcgyn\u00f6ks\u00e9g<\/a> r\u00f6vid, magyar betegt\u00e1j\u00e9koztat\u00f3it \u00e9rik el.<\/p>\n<p style=\"text-align: justify\">Fontos tudni, hogy a kezel\u0151orvosa minden esetben \u00e1tbesz\u00e9li a betegekkel az alkalmazott kezel\u00e9st, annak v\u00e1rhat\u00f3 mell\u00e9khat\u00e1sait \u00e9s t\u00e1j\u00e9koztat\u00e1st ad, hogy milyen utas\u00edt\u00e1sokat kell betartania a gy\u00f3gyszer alkalmaz\u00e1sa vagy a kezel\u00e9s sor\u00e1n.<\/p>\n<p style=\"text-align: justify\">Az egyes gy\u00f3gyszerekkel kapcsolatos r\u00e9szletes hivatalos betegt\u00e1j\u00e9koztat\u00f3k megtal\u00e1lhat\u00f3ak a magyar gy\u00f3gyszerhat\u00f3s\u00e1g, az Orsz\u00e1gos Gy\u00f3gyszer\u00e9szeti- \u00e9s \u00c9lelmez\u00e9s-eg\u00e9szs\u00e9g\u00fcgyi Int\u00e9zet <a href=\"https:\/\/ogyei.gov.hu\/gyogyszeradatbazis\" target=\"_blank\" rel=\"noopener\">honlapj\u00e1n<\/a>. Tov\u00e1bbi hasznos tudnival\u00f3kat olvashat az <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\">Eur\u00f3pai Gy\u00f3gyszer\u00fcgyn\u00f6ks\u00e9g honlapj\u00e1n<\/a> (angol \u00e9s magyar nyelv\u0171 \u00f6sszefoglal\u00f3k)<\/p>\n<h4><strong>Hat\u00f3anyag neve (z\u00e1r\u00f3jelben a term\u00e9kn\u00e9v tal\u00e1lhat\u00f3):<\/strong><\/h4>\n<ul>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/verzenios-epar-medicine-overview_hu.pdf\" target=\"_blank\" rel=\"noopener\">abemaciklib (Verzenios)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/piqray-epar-medicine-overview_hu.pdf\" target=\"_blank\" rel=\"noopener\">alpelisib (Piqray)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/tecentriq-epar-medicine-overview_hu.pdf\" target=\"_blank\" rel=\"noopener\">atezolizumab (Tecentriq)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/avastin-epar-summary-public_hu.pdf\" target=\"_blank\" rel=\"noopener\">bevacizumab (Avastin)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/xeloda-epar-summary-public_hu.pdf\" target=\"_blank\" rel=\"noopener\">capecitabine (Xeloda)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/erbitux-epar-summary-public_hu.pdf\" target=\"_blank\" rel=\"noopener\">cetuximab (Erbitux)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/xgeva-epar-medicine-overview_hu.pdf\" target=\"_blank\" rel=\"noopener\">denosumab (Xgeva)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/docetaxel-accord-epar-medicine-overview_hu.pdf\">docetaxel<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/caelyx-pegylated-liposomal-epar-medicine-overview_hu.pdf\">doxorubicin (liposz\u00f3m\u00e1lis, pegil\u00e1lt &#8211; Caelyx) <\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/afinitor-epar-summary-public_hu.pdf\" target=\"_blank\" rel=\"noopener\">everolimus (Afinitor)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/glivec-epar-summary-public_hu.pdf\" target=\"_blank\" rel=\"noopener\">imatinib (Glivec)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/yervoy-epar-medicine-overview_hu.pdf\" target=\"_blank\" rel=\"noopener\">ipilimumab (Yervoy)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/tyverb-epar-medicine-overview_hu.pdf\" target=\"_blank\" rel=\"noopener\">lapatinib (Tyverb)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/opdivo-epar-medicine-overview_hu.pdf\" target=\"_blank\" rel=\"noopener\">nivolumab (Opdivo)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/lynparza-epar-medicine-overview_hu.pdf\" target=\"_blank\" rel=\"noopener\">olaparib (Lynparza)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/abraxane-epar-summary-public_hu.pdf\">paclitaxel (albumin hum\u00e1n proteinhez kapcsol\u00f3d\u00f3 \u2013 Abraxane)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/ibrance-epar-summary-public_hu.pdf\" target=\"_blank\" rel=\"noopener\">palbociklib (Ibrance)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/vectibix-epar-medicine-overview_hu.pdf\" target=\"_blank\" rel=\"noopener\">panitumumab (Vectibix)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/keytruda-epar-medicine-overview_hu.pdf\" target=\"_blank\" rel=\"noopener\">pembrolizumab (Keytruda)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/perjeta-epar-medicine-overview_hu.pdf\" target=\"_blank\" rel=\"noopener\">pertuzumab (Perjeta)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/kisqali-epar-medicine-overview_hu.pdf\" target=\"_blank\" rel=\"noopener\">ribociklib (Kisqali)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/trodelvy-epar-medicine-overview_hu.pdf\" target=\"_blank\" rel=\"noopener\">sacituzumab-govitecan (Trodelvy)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/nexavar-epar-summary-public_hu.pdf\" target=\"_blank\" rel=\"noopener\">sorafenib (Nexavar)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/topotecan-hospira-epar-summary-public_hu.pdf\">topotecan<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/herceptin-epar-summary-public_hu.pdf\" target=\"_blank\" rel=\"noopener\">trastuzumab (Herceptin)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/kadcyla-epar-summary-public_hu.pdf\" target=\"_blank\" rel=\"noopener\">trastuzumab emtansine (Kadcyla)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/tukysa-epar-medicine-overview_hu.pdf\" target=\"_blank\" rel=\"noopener\">tukatinib (Tukysa)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/hu\/documents\/overview\/zoledronic-acid-accord-epar-medicine-overview_hu.pdf\">zoledronsav <\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>A mindennapi onkol\u00f3giai ell\u00e1t\u00e1sban rendk\u00edv\u00fcl sok daganatellenes k\u00e9sz\u00edtm\u00e9nyt alkalmaznak. Az al\u00e1bbiakban a leggyakrabban haszn\u00e1lt gy\u00f3gyszerek r\u00f6vid, k\u00f6z\u00e9rthet\u0151 \u00f6sszefoglal\u00f3inak linkgy\u0171jtem\u00e9ny\u00e9t tal\u00e1lja. Az egyes gy\u00f3gyszerek nev\u00e9re kattintva az <a href=\"https:\/\/www.ema.europa.eu\/\" target=\"_blank\" rel=\"noopener\">Eur\u00f3pai Gy\u00f3gyszer\u00fcgyn\u00f6ks\u00e9g<\/a> r\u00f6vid, magyar betegt\u00e1j\u00e9koztat\u00f3it \u00e9rik el. Fontos tudni, hogy a kezel\u0151orvosa minden esetben \u00e1tbesz\u00e9li a betegekkel az alkalmazott kezel\u00e9st, annak v\u00e1rhat\u00f3 mell\u00e9khat\u00e1sait \u00e9s t\u00e1j\u00e9koztat\u00e1st ad, hogy milyen utas\u00edt\u00e1sokat kell betartania &hellip;<\/p>\n","protected":false},"author":101105,"featured_media":0,"parent":11,"menu_order":6,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"categories":[],"tags":[],"class_list":["post-1401","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/onkologiai-kozpont\/wp-json\/wp\/v2\/pages\/1401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/onkologiai-kozpont\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/semmelweis.hu\/onkologiai-kozpont\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/onkologiai-kozpont\/wp-json\/wp\/v2\/users\/101105"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/onkologiai-kozpont\/wp-json\/wp\/v2\/comments?post=1401"}],"version-history":[{"count":12,"href":"https:\/\/semmelweis.hu\/onkologiai-kozpont\/wp-json\/wp\/v2\/pages\/1401\/revisions"}],"predecessor-version":[{"id":3343,"href":"https:\/\/semmelweis.hu\/onkologiai-kozpont\/wp-json\/wp\/v2\/pages\/1401\/revisions\/3343"}],"up":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/onkologiai-kozpont\/wp-json\/wp\/v2\/pages\/11"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/onkologiai-kozpont\/wp-json\/wp\/v2\/media?parent=1401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/onkologiai-kozpont\/wp-json\/wp\/v2\/categories?post=1401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/onkologiai-kozpont\/wp-json\/wp\/v2\/tags?post=1401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}